Drug Profile
Research programme: CXCR4 inhibitors - Kureha
Alternative Names: CS-3955; KRH-3955Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Kureha Corporation
- Class
- Mechanism of Action CXCR4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in HIV-infections in Japan (PO)
- 07 May 2009 Preclinical trials in HIV infections in Japan (PO)
- 12 May 2008 No development reported - Preclinical for HIV infections in Japan (PO)